Comparison of tafluprost and latanoprost on progression of visual field loss in primary open angle glaucoma: prospective, randomized, open, multi-center study.

Comparison of tafluprost and latanoprost on progression of visual field loss in primary open angle glaucoma: prospective, randomized, open, multi-center study. - Comparison of tafluprost and latanoprost on progression of visual field loss in primary open angle glaucoma

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004093

Enrollment

120

Registered

2010-10-31

Start date

2010-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma

Interventions

The subjects are instilled the 0.0015% tafluprost ophthalmic solution once a day for 36 months. The subjects are visited a hospital at every 3 month intervals and measured intraocular pressure and exa

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with 0.005% latanoprost monotherapy over 3 months at time when obtain a patient's consent. 2. Diagnosed patients with glaucomatous visual field loss at least one eye. Patients with MD value between -20 dB to -3 dB. 3. Patients with diurnal IOP less than or equal to 19 mmHg. 4. Diagnosed patients with open angle as Grade 3 or 4 of Shaffer's classification

Exclusion criteria

Exclusion criteria: 1. Patients had not reliable visual field measurements (fixation loss of less than 20%, and a false-negative rate and a false-positive rate of less than 33%) 2. Any corneal abnormality or other condition preventing reliable applanation tonometry. 3. Require concomitant IOP-lowering medication or glaucoma surgery 4. Refractive error in spherical equivalent exceed -8D or +8D. 5. Patient under treatment with steroids. 6. History of cataracta surgery within 6 months before start of study. 7. History of glaucoma surgery including laser iridectomy and trabeculoplasty. 8. Presence of any active external ocular disease, inflammation or infection of the eye and/or eyelids. 9. Presence of ocular disease preventing reliable visual field measurements.

Design outcomes

Primary

Measure	Time frame
Change of visual field parameters	—

Secondary

Measure	Time frame
Change of intraocular pressure	—

Countries

Japan

Contacts

Public ContactMakoto Ishikawa

Akita University, School of Medicine Department of Ophthalmology

michinok@med.akita-u.ac.jp018-834-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026